Colorectal cancer is a common malignant tumor in China. In Beijing, for example, the incidence rate of colorectal cancer is 24.2/100,000 for men and 23.5/100,000 for women. Liver metastasis occurs in about 25%-30% of patients at the same time or within 6 months of the diagnosis of colorectal cancer, and nearly 50%-75% of patients will eventually develop liver metastasis in the late stage of the disease. Liver metastasis is the end-stage manifestation of colorectal patients, and many patients or family members who have liver metastasis from colorectal cancer will lose their confidence and hope in treatment. Indeed, the survival period of untreated colorectal cancer patients with liver metastases often does not exceed 1 year. The development and application of new chemotherapy drugs have improved the survival of patients with liver metastases, but the median survival is only about 15 to 18 months. With the accumulation of experience in the treatment of colorectal cancer liver metastases, surgical resection is considered to be the only possible means to obtain a cure for patients with colorectal cancer liver metastases. It has been reported that the 5-year survival rate of patients with liver metastases from colorectal cancer resected by surgery can reach 20%-58%, with a median survival of 21-46 months. However, only 20% of patients with liver metastases from colorectal cancer can actually undergo radical resection, and the vast majority of patients cannot be surgically resected. Recent studies have shown that preoperative neoadjuvant chemotherapy can convert unresectable colorectal cancer liver metastases into resectable ones and improve the rate of surgical resection.Giacchetti et al. retrospectively analyzed 389 patients with colorectal cancer liver metastases, of whom 151 patients with inoperable resectable metastases were treated with oxaliplatin and 5-Fu regimen chemotherapy, 38% of them could undergo radical metastasectomy and the median survival time after surgery was 48 months. The median survival time was 48 months, while the median survival time for inoperable patients was only 15.5 months. In the treatment of patients with liver metastases from colorectal cancer, the choice of treatment plan is the core issue: should chemotherapy or surgery be performed first? Should the primary cancer and metastatic cancer be resected at the same time or in stages? What is the choice of chemotherapy? Is it necessary to add molecular targeted therapy drugs? These are the practical issues faced by physicians treating patients with liver metastases from colorectal cancer. Along with the refinement of medical subspecialties and the rapid development of various subspecialties, it is very difficult to solve these problems by specialists of one discipline alone, which requires a multidisciplinary team treatment model (MDT model). The MDT model has been recognized and recommended by many governments and associations in the process of cancer diagnosis and treatment. It has been promoted and improved. Gastrointestinal Surgery Department of Peking University People’s Hospital established MDT in 2000, which includes experts in internal medicine, surgery, pathology, medical imaging and other disciplines, and all colorectal cancer patients are discussed by a multidisciplinary group of experts before deciding on the treatment plan.